Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Conversion Labs Inc (CVLB)

Conversion Labs Inc (CVLB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 681,521
  • Shares Outstanding, K 23,181
  • Annual Sales, $ 12,470 K
  • Annual Income, $ -3,140 K
  • 60-Month Beta 1.05
  • Price/Sales 24.05
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CVLB with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.25
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 03/30/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.27
  • Number of Estimates 1
  • High Estimate -0.27
  • Low Estimate -0.27
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -440.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.60 +286.84%
on 01/20/21
33.02 -10.96%
on 02/10/21
+21.65 (+279.35%)
since 01/19/21
3-Month
5.81 +406.02%
on 01/04/21
33.02 -10.96%
on 02/10/21
+21.85 (+289.40%)
since 11/19/20
52-Week
0.50 +5,780.00%
on 03/13/20
33.02 -10.96%
on 02/10/21
+28.70 (+4,130.22%)
since 02/19/20

Most Recent Stories

More News
Conversion Labs Begins Trading Under New Company Name, LifeMD, and Ticker Symbol, LFMD

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc .  (NASDAQ: CVLB) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, will begin trading at the opening of the market...

CVLB : 29.40 (+0.31%)
LFMD : 9.32 (+0.22%)
Conversion Labs to Present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021

NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc.  (NASDAQ: CVLB), a leading direct-to-patient telehealth company, has been invited to present at the BTIG Virtual MedTech, Digital...

CVLB : 29.40 (+0.31%)
Conversion Labs to Become Life MDâ„¢ with Launch of New Concierge Telehealth Services

Company Completes $14 Million Unregistered Private Placement with Strategic Institutional Investors to Support Nationwide Launch of New Telehealth Service Offerings

CVLB : 29.40 (+0.31%)
Conversion Labs Appoints Seasoned Financial and Operational Executive, Marc Benathen, as Chief Financial Officer

NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc .  (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, has appointed Marc Benathen as chief financial officer,...

CVLB : 29.40 (+0.31%)
Conversion Labs Increases Stake in Fast-Growing SaaS Subsidiary

NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc .  (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, has increased its stake in its legacy LegalSimpli Software...

CVLB : 29.40 (+0.31%)
Conversion Labs Expects 2020 Revenue up 205% to Record $38.0 Million, Subscription ARR up 525% to $26.0 Million

NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc .  (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, reported preliminary unaudited results for its fourth quarter...

CVLB : 29.40 (+0.31%)
Conversion Labs Appoints Leading Telehealth Professional, Dr. Anthony Puopolo, as Chief Medical Officer

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc .  (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed licensed personal care and wellness physician and psychiatrist,...

CVLB : 29.40 (+0.31%)
Conversion Labs to Present at the H.C. Wainwright Virtual BioConnect Conference on January 11, 2021

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc.  (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has been invited to present at H.C. Wainwright’s BioConnect Conference...

CVLB : 29.40 (+0.31%)
Conversion Labs Appoints Digital Marketing Executive, Bryant Hussey, as Chief Digital Officer

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc.  (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed digital marketing expert and industry thought-leader, ...

CVLB : 29.40 (+0.31%)
Conversion Labs Annualized Revenue Run-Rate Hits $53.9 Million, up 332% vs. 2019, Driven by Subscriptions to an Expanding Suite of Telehealth Brands

NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc .  (NASDAQ: CVLB), a direct-to-consumer telemedicine and wellness company, reported its annualized revenue run-rate reached a record...

CVLB : 29.40 (+0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Conversion Labs Inc is a health and wellness focused e-commerce company. Its portfolio of brands includes proprietary over-the-counter products and prescription medications. Conversion Labs Inc., formerly known as Immudyne Inc., is based in New York.

See More

Key Turning Points

3rd Resistance Point 32.08
2nd Resistance Point 31.21
1st Resistance Point 30.30
Last Price 29.40
1st Support Level 28.52
2nd Support Level 27.65
3rd Support Level 26.74

See More

52-Week High 33.02
Last Price 29.40
Fibonacci 61.8% 20.60
Fibonacci 50% 16.76
Fibonacci 38.2% 12.92
52-Week Low 0.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar